On November 18, 2021 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, reported that it is giving notice of its intention to redeem the following Senior Notes (the "Redemption"), representing an aggregate total principal amount of approximately $2.2 billion, on December 3, 2021 (the "Redemption Date") (Press release, Thermo Fisher Scientific, NOV 18, 2021, View Source [SID1234595826]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

$1.1 billion aggregate principal amount of 4.133% Senior Notes due 2025 (the "2025 Notes"); and
$1.1 billion aggregate principal amount of 4.497% Senior Notes due 2030 (the "2030 Notes" and, together with the 2025 Notes, the "Notes").
The Notes will be redeemed at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of the Notes to be redeemed discounted to the Redemption Date on a semi-annual basis at a comparable treasury rate plus 50 basis points in the case of both the 2025 Notes and the 2030 Notes, plus, in each case, accrued and unpaid interest on the Notes to be redeemed to, but excluding, the Redemption Date. Thermo Fisher intends to fund the Redemption using cash on hand.